论文部分内容阅读
美国FDA于2013年12月18日批准葛兰素史克公司(GlaxoSmithKline)研发的新药Anoro Ellipta用于对慢性阻塞性肺病(COPD)患者的气流阻塞症状进行长期维持治疗。Anoro Ellipta是一种复方药,有效成分为umeclidinium(一种抗胆碱药)与维兰特罗(vilanterol,一种长效β2肾上腺素能受体激动剂),剂型为吸入性粉末,剂量为1日1次。其作用机制是帮助COPD患者肺部的气道保持松弛状态,从而增加气流量。COPD是一种严重的肺病,其主要病因是吸烟,其症状包括胸闷、咳嗽、多痰等。据美国国立心肺血液研究院
On December 18, 2013, the U.S. FDA approved the use of Anoro Ellipta, a new drug developed by GlaxoSmithKline, for the long-term maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Anoro Ellipta is a combination drug consisting of umeclidinium (an anticholinergic) and vilanterol (a long-acting β 2 adrenergic receptor agonist) in an inhalable powder at a dose of 1 day Times. Its mechanism of action is to help the COPD patients maintain a relaxed airway in the lungs, thereby increasing the amount of air flow. COPD is a serious lung disease, the main cause is smoking, the symptoms include chest tightness, cough, sputum and so on. According to the American National Heart, Lung and Blood Institute